One‐year clinical outcomes after sirolimus‐eluting coronary stent implantation in diabetics enrolled in the worldwide e‐SELECT registry

Diabetes mellitus has worse outcome after percutaneous coronary intervention.

[1]  Maarten J. IJzerman,et al.  Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial. , 2014, American heart journal.

[2]  H. Wijeysundera,et al.  Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. , 2013, JAMA.

[3]  J. Rutledge,et al.  Coronary artery revascularization in patients with diabetes mellitus. , 2013, Circulation.

[4]  M. Mack,et al.  Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  A. Yeung,et al.  Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. , 2013, JACC. Cardiovascular interventions.

[6]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[7]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. , 2013, European heart journal.

[8]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[9]  A. Kirtane,et al.  Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials , 2012, BMJ : British Medical Journal.

[10]  H. Bøtker,et al.  Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). , 2011, The American journal of cardiology.

[11]  M. Jeong,et al.  Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. , 2011, Journal of the American College of Cardiology.

[12]  L. Eckardt,et al.  Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). , 2010, The American journal of cardiology.

[13]  Takahiko Suzuki,et al.  Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis. , 2010, JACC. Cardiovascular interventions.

[14]  L. Eckardt,et al.  Outcomes after differential use of drug‐eluting stents in diabetic patients: 1‐Year results from the DES.DE (Drug‐Eluting Stent.DEutschland) registry , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  Ajay K. Jain,et al.  Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry , 2010, Heart.

[16]  Sunil V. Rao,et al.  Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years , 2010, Circulation. Cardiovascular interventions.

[17]  E. Edelman,et al.  Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting , 2010, Reviews in Endocrine and Metabolic Disorders.

[18]  G. Angelini,et al.  Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. , 2010, Journal of the American College of Cardiology.

[19]  W. Laskey,et al.  Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus: A Report From the National Heart, Lung, and Blood Institute Dynamic Registry , 2010, Circulation. Cardiovascular interventions.

[20]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[21]  A. Kirtane,et al.  5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. , 2009, Journal of the American College of Cardiology.

[22]  Sunil V. Rao,et al.  Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.

[23]  Y. Hayashi,et al.  Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.

[24]  Dick M. Goedhart,et al.  Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. , 2010, Journal of the American College of Cardiology.

[25]  V. Fuster,et al.  Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. , 2008, American heart journal.

[26]  A. Colombo,et al.  Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.

[27]  S. Pocock,et al.  Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. , 2007, European heart journal.

[28]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[29]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[30]  B. Gersh,et al.  Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry , 2007 .

[31]  E. Bramucci,et al.  Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.

[32]  S. Steinhubl,et al.  Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. , 2006, The New England journal of medicine.

[33]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[34]  Robert M Califf,et al.  A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[35]  R. Seabra-Gomes,et al.  Percutaneous coronary interventions with drug eluting stents for diabetic patients , 2005, Heart.

[36]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[37]  F. Cosentino,et al.  Diabetes and Inflammation , 2004, Herz.

[38]  W. O’Neill,et al.  Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.

[39]  N. Weissman,et al.  Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. , 2003, The American journal of cardiology.

[40]  E. Topol,et al.  Neointimal Hyperplasia After Arterial Injury Is Increased in a Rat Model of Non–Insulin-Dependent Diabetes Mellitus , 2001, Circulation.

[41]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.